Background: Weight management strategies are central to the control and remission of type 2 diabetes (T2D). Yet, scalable interventions remain elusive. We report the real-world outcomes of a scalable, digitally-enabled lifestyle program utilizing diabetes-specific nutrition formula (DSNF) as part of a low-calorie diet for people with obesity and T2D.

Methods: 185 adult participants with recently diagnosed T2D and 27 ≤BMI≤ 45 kg/m2 were recruited from 28 primary care practices (Newcastle upon Tyne, UK). The 12-week weight loss phase included the use of a DSNF (Glucerna®, Abbott) as part of a low-calorie diet (900-1000 kcal/day). The diet was personalized, allowing use of Glucerna® for meal replacement, real food, or a combination of both. Anti-hyperglycemic medication was withdrawn while clinical care remained with the primary clinicians. Behavioral coaching was offered digitally alongside educational content, interactive quizzes, and diet planners.

Results: Participants (55±9 years, 53% male, 70% White) engaged well with the digital service, with 78% (n=145) completing the weight loss phase. Content engagement was high (average 360 minutes content read; 60 minutes 1:1 coaching across five sessions); Glucerna® adherence was >80%. A significant 10% weight loss reduction (-10 kg [95%CI: -12, -8]) and ~1% HbA1c reduction (10.9 mmol/mol [95%CI: -11,-7]) were reported at 3 months. Significant reduction in blood pressure was also reported (p-values<0.01). No significant differences were observed between intent-to-treat and evaluable cohorts.

Conclusions: A remote, digitally-enabled lifestyle program using a DSNF as part of a low-calorie diet significantly improved body weight and diabetes control in people with obesity and T2D.

Disclosure

M. Trenell: Consultant; Changing Health, Abbott Nutrition. L.C. Taylor: Employee; Changing Health Ltd. K.W. Kerr: Employee; Abbott. Stock/Shareholder; Abbott. R. Rueda: Employee; Abbott Nutrition. S. Sulo: Employee; Abbott Nutrition.

Funding

Financial support for this study was provided by Abbott and UK Research and Innovation.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.